New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
07:23 EDTAUXLUBS calls Auxilium a 'sleeper pick' for 2014
UBS believes investors are overlooking Auxilium's highly leveraged business model which will be driven by strong Xiaflex, Stendra, and Testopel growth, and stabilizing Testim. The firm expects operating margins to move towards 30% by 2016-17 from approximately 10% in 2013 and a pathway for 30% stock return performance over the next year. Shares are Buy rated with a $30 price target, up from $23.
News For AUXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
06:13 EDTAUXLAuxilium reports Q3 EPS 27c, consensus 10c
Subscribe for More Information
October 21, 2014
08:13 EDTAUXLBioSpecifics announces FDA approval of sBLA for XIAFLEX
Subscribe for More Information
October 20, 2014
17:33 EDTAUXLAuxilium announces XIAFLEX approved for treatment of up to two DC joints
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use